Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.55 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391582 | 1.00 | GSK3B (0.60) | GSK3BPTPN1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL29628344 | 0.86 | TAS1R3 (0.44) | GSK3BPTPN1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL3973133 | 0.85 | GSK3B (0.55) | GSK3BPTPN1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL29499477 | 0.85 | GSK3B (0.55) | GSK3BPTPN1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL7144096 | 0.83 | GSK3B (0.59) | GSK3BKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL27503767 | 0.83 | KCNQ3 (0.44) | KCNQ3KCNQ2KCNE1KCNQ1TSHR | |
| SCHEMBL747174 | 0.82 | GSK3B (0.61) | GSK3BPTPN1TSHR | |
| SCHEMBL29514695 | 0.82 | GSK3B (0.61) | GSK3BPTPN1TSHR | |
| SCHEMBL29628387 | 0.82 | PTPN1 (0.61) | GSK3BPTPN1NPC1RAB9A | |
| SCHEMBL366866 | 0.82 | PTPN1 (0.61) | GSK3BPTPN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516046-B2 | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4232448-B1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2025-05-07 | — | — | EP | disclosed |
| EP-3956323-B1 | OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 | Halo Therapeutics Ltd (GB) | 2025-03-05 | — | — | EP | disclosed |
| EP-3997096-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | Halo Therapeutics Ltd (GB) | 2024-05-16 | — | — | US | disclosed |
| US-11802122-B2 | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230312528-A1 | 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4232448-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2023-08-30 | — | — | EP | disclosed |
| US-20230227441-A1 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| WO-2009130232-A1 | PYRAZOLO [1, 5 -A] PYRAZINE DERIVATIVES AS ANTAGONISTS OF V1B RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130231-A1 | PYRROLO [1, 2-A] PYRAZINE DERIVATIVES AS VASOPRESSIN VIB RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009129109-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2008140947-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2000066578-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | FFAR1, FFAR2, FFAR3 | GSK3B 4031/4885PTPN1 991/4885KCNQ3 3881/4885 |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | GSK3B 1521/4885PTPN1 1786/4885KCNQ3 4696/4885 |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | GSK3B 546/4885PTPN1 1121/4885KCNQ3 2917/4885 |
| US-20230227441-A1 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | GSK3B 2208/4885PTPN1 1717/4885KCNQ3 122/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | GSK3B 174/4885PTPN1 57/4885KCNQ3 4530/4885 |
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | GSK3B 1100/4885PTPN1 494/4885KCNQ3 2538/4885 |
| US-11802122-B2 | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors | SCN8A, TRPV1, SCN2A | GSK3B 3309/4885PTPN1 2148/4885KCNQ3 111/4885 |
| US-20230312528-A1 | 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | GSK3B 3566/4885PTPN1 1960/4885KCNQ3 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.